{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T09:18:35Z","timestamp":1789377515115,"version":"build-2803163510"},"reference-count":115,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.jaut.2016.06.014","type":"journal-article","created":{"date-parts":[[2016,7,2]],"date-time":"2016-07-02T15:09:26Z","timestamp":1467472166000},"page":"94-105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["Success and failure of biological treatment in systemic lupus erythematosus: A critical analysis"],"prefix":"10.1016","volume":"74","author":[{"given":"Mariele","family":"Gatto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3527-1954","authenticated-orcid":false,"given":"Francesca","family":"Saccon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Zen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvano","family":"Bettio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Iaccarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Punzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Doria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2016.06.014_bib1","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.amjmed.2005.11.034","article-title":"Long-term prognosis and causes of death in systemic lupus erythematosus","volume":"119","author":"Doria","year":"2006","journal-title":"Am. J. Med."},{"key":"10.1016\/j.jaut.2016.06.014_bib2","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/art.30293","article-title":"Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006","volume":"63","author":"Costenbader","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2016.06.014_bib3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3899\/jrheum.080625","article-title":"Changes in the incidence of endstage renal disease due to lupus nephritis in the United States, 1996\u20132004","volume":"36","author":"Ward","year":"2009","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.jaut.2016.06.014_bib4","first-page":"1955","article-title":"Accrual of organ damage over time in patients with systemic lupus erythematosus","volume":"30","author":"Gladman","year":"2003","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.jaut.2016.06.014_bib5","article-title":"In-\/off-label use of biologic therapy in systemic lupus erythematosus","volume":"17","author":"Gatto","year":"2014","journal-title":"BMC Med."},{"key":"10.1016\/j.jaut.2016.06.014_bib6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrrheum.2013.140","article-title":"The landscape of comparative effectiveness research in rheumatology","volume":"10","author":"DeWitt","year":"2014","journal-title":"Nat. Rev. Rheumatol."},{"issue":"Suppl.\u00a04","key":"10.1016\/j.jaut.2016.06.014_bib7","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1186\/ar3919","article-title":"Unmet medical needs in systemic lupus erythematosus","volume":"14","author":"Lateef","year":"2012","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2016.06.014_bib8","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.autrev.2014.01.055","article-title":"Optimizing outcome in SLE: treating-to-target and definition of treatment goals","volume":"13","author":"Doria","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2016.06.014_bib9","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1191\/096120301670679959","article-title":"Early damage as measured by the SLICC\/ACR damage index is a predictor of mortality in systemic lupus erythematosus","volume":"10","author":"Rahman","year":"2001","journal-title":"Lupus."},{"key":"10.1016\/j.jaut.2016.06.014_bib10","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1177\/0961203310366572","article-title":"Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus","volume":"19","author":"Nossent","year":"2010","journal-title":"Lupus."},{"key":"10.1016\/j.jaut.2016.06.014_bib11","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1177\/0961203314559087","article-title":"Value and goals of treat-to-target in systemic lupus erythematosus: knowledge and foresight","volume":"24","author":"Doria","year":"2015","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2016.06.014_bib12","first-page":"1467","article-title":"Prolonged remission in systemic lupus erythematosus","volume":"32","author":"Urowitz","year":"2005","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.jaut.2016.06.014_bib13","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.3899\/jrheum.100007","article-title":"Prolonged serologically active clinically quiescent systemic lupus erythematosus: frequency and outcome","volume":"37","author":"Steiman","year":"2010","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.jaut.2016.06.014_bib14","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1136\/annrheumdis-2015-207347","article-title":"Prolonged remission in Caucasian patients with SLE: prevalence and outcomes","volume":"74","author":"Zen","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2016.06.014_bib15","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/art.10763","article-title":"LJP 394 Investigator Consortium. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study","volume":"48","author":"Alarc\u00f3n-Segovia","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2016.06.014_bib16","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1002\/art.23673","article-title":"LJP 394-90-09 Investigator Consortium. Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial","volume":"58","author":"Cardiel","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2016.06.014_bib17","doi-asserted-by":"crossref","first-page":"R33","DOI":"10.1186\/ar3738","article-title":"Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial","volume":"14","author":"Ginzler","year":"2012","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2016.06.014_bib18","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis. The lupus nephritis assessment with rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2016.06.014_bib19","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.38037","article-title":"Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study","volume":"65","author":"Mysler","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2016.06.014_bib20","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/art.38260","article-title":"Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study","volume":"66","author":"Furie","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2016.06.014_bib21","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.38790","article-title":"Treatment of lupus nephritis with abatacept: the abatacept and cyclophosphamide combination efficacy and safety study","volume":"66","author":"ACCESS Trial Group","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2016.06.014_bib22","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1002\/art.10681","article-title":"IDEC-131 Lupus Study Group. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial","volume":"46","author":"Kalunian","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2016.06.014_bib23","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1002\/art.24699","article-title":"A\u00a0phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus","volume":"61","author":"Wallace","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2016.06.014_bib24","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1002\/art.27601","article-title":"The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2016.06.014_bib25","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2016.06.014_bib26","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2016.06.014_bib27","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A\u00a0phase 3, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits BLyS, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2016.06.014_bib28","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1136\/annrheumdis-2012-202460","article-title":"Lupuzor\/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial","volume":"72","author":"Zimmer","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2016.06.014_bib29","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1093\/rheumatology\/ket129","article-title":"Efficacy and safety of epratuzumab in patients with moderate\/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up","volume":"52","author":"Wallace","year":"2013","journal-title":"Rheumatol. Oxf."},{"key":"10.1016\/j.jaut.2016.06.014_bib30","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1136\/annrheumdis-2012-202760","article-title":"Efficacy and safety of epratuzumab in patients with moderate\/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study","volume":"73","author":"Wallace","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2016.06.014_bib31","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1136\/annrheumdis-2013-205067","article-title":"Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)","volume":"74","author":"Isenberg","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2016.06.014_bib32","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/annrheumdis-2014-206090","article-title":"A\u00a0Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-\u03b1) in patients with systemic lupus erythematosus (ROSE)","volume":"75","author":"Kalunian","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2016.06.014_bib33","unstructured":"R. Furie, J.T. Merrill, V. Werth, M. Kamashta, K. Kalunian, P. Brohawn, et\u00a0al. Anifrolumab, an anti-interferon alpha receptor monoclonal antibody, in moderate to severe SLE. Abstract no. 3223 presented at the ACR\/ARHP annual meeting, San Francisco, CA, November 6\u201311, 2015."},{"key":"10.1016\/j.jaut.2016.06.014_bib34","unstructured":"W. Stohl, A. Schwarting, M. Okada, M. Scheinberg, A. Doria, A. Hammer, et\u00a0al. A Randomized, Double-Blind, Placebo-Controlled, 52-Week Study of the Efficacy and Safety of Belimumab Administered Subcutaneously Plus Standard Care to Patients with Systemic Lupus Erythematosus (SLE). Abstract no. 3218 presented at the ACR\/ARHP annual meeting, San Francisco, CA, November 6\u201311, 2015."},{"key":"10.1016\/j.jaut.2016.06.014_bib35","doi-asserted-by":"crossref","first-page":"e000104","DOI":"10.1136\/lupus-2015-000104","article-title":"Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus: results of phase II study","volume":"11","author":"Urowitz","year":"2015","journal-title":"Lupus. Sci. Med."},{"key":"10.1016\/j.jaut.2016.06.014_bib36","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1136\/annrheumdis-2013-205144","article-title":"PEARL-SC Study. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study","volume":"74","author":"Furie","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2016.06.014_bib37","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/annrheumdis-2015-207653","article-title":"Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study","volume":"75","author":"Isenberg","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2016.06.014_bib38","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/annrheumdis-2015-207654","volume":"75","author":"Merrill","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2016.06.014_bib39","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2015-208562","article-title":"CD1067 study investigators. Sifalimumab, an anti-interferon-\u03b1 monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study","author":"Khamashta","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2016.06.014_bib40","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrrheum.2013.145","article-title":"Treatment of systemic lupus erythematosus: new therapeutic avenues and blind alleys","volume":"10","author":"Thanou","year":"2014","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.jaut.2016.06.014_bib41","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1053\/berh.2002.0259","article-title":"Epidemiology of systemic lupus erythematosus","volume":"16","author":"Petri","year":"2002","journal-title":"Best. Pract. Res. Clin. Rheumatol."},{"key":"10.1016\/j.jaut.2016.06.014_bib42","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.autrev.2012.09.003","article-title":"Emerging and critical issues in the pathogenesis of lupus","volume":"12","author":"Gatto","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2016.06.014_bib43","first-page":"856","article-title":"Disease activity patterns in a monocentric cohort of SLE patients: a seven-year follow-up study","volume":"30","author":"Zen","year":"2012","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jaut.2016.06.014_bib44","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1002\/1529-0131(199912)42:12<2682::AID-ANR26>3.0.CO;2-6","article-title":"Patterns of disease activity in systemic lupus erythematosus","volume":"42","author":"Barr","year":"1999","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2016.06.014_bib45","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1177\/0961203313483376","article-title":"Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis","volume":"22","author":"Davies","year":"2013","journal-title":"Lupus"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.jaut.2016.06.014_bib46","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/ar3910","article-title":"B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design","volume":"15","author":"Reddy","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2016.06.014_bib47","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/art.24698","article-title":"Novel evidence-based systemic lupus erythematosus responder index","volume":"61","author":"Furie","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2016.06.014_bib48","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nrneph.2016.20","article-title":"Plasma cells as an innovative target in autoimmune disease with renal manifestations","volume":"12","author":"Hiepe","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.jaut.2016.06.014_bib49","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1177\/0961203313509295","article-title":"Rituximab in systemic lupus erythematosus: an updated systematic review and metanalysis","volume":"22","author":"Duxbury","year":"2013","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2016.06.014_bib50","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1093\/ndt\/gfp336","article-title":"Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids","volume":"24","author":"Pepper","year":"2009","journal-title":"Nephrol. Dial. Transpl."},{"key":"10.1016\/j.jaut.2016.06.014_bib51","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/rheumatology\/ker337","article-title":"Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen","volume":"52","author":"Ezeonyeji","year":"2012","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2016.06.014_bib52","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.autrev.2015.07.017","article-title":"A\u00a04-year observation in lupus nephritis patients treated with an intensified B-lymphocyte depletion without immunosuppressive maintenance treatment-Clinical response compared to literature and immunological re-assessment","volume":"14","author":"Roccatello","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2016.06.014_bib53","doi-asserted-by":"crossref","DOI":"10.1177\/0961203316641768","article-title":"Risk of clinical deterioration in patients with lupus nephritis using rituximab","author":"Manou-Stathopolou","year":"2016","journal-title":"Lupus."},{"key":"10.1016\/j.jaut.2016.06.014_bib54","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3109\/14397595.2015.1060665","article-title":"Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy","volume":"26","author":"Tanaka","year":"2016","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.jaut.2016.06.014_bib55","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/rheumatology\/kep124","article-title":"Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis?","volume":"48","author":"Li","year":"2009","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2016.06.014_bib56","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/ndt\/gfs285","article-title":"Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis","volume":"28","author":"Weidenbusch","year":"2013","journal-title":"Nephrol. Dial. Transpl."},{"key":"10.1016\/j.jaut.2016.06.014_bib57","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/art.34362","article-title":"The landscape after LUNAR: rituximab\u2019s crater-filled path","volume":"64","author":"Lightstone","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2016.06.014_bib58","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.autrev.2010.08.012","article-title":"The administration of low doses of rituximab followed by hydroxychloroquine, prednisone and low doses of mycophenolate mofetil is an effective therapy in Latin American patients with active systemic lupus erythematosus","volume":"10","author":"Galarza-Maldonado","year":"2010","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2016.06.014_bib59","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1159\/000368585","article-title":"Rituximab in systemic lupus erythematosus and lupus nephritis","volume":"128","author":"Beckwith","year":"2014","journal-title":"Nephron. Clin. Pract."},{"key":"10.1016\/j.jaut.2016.06.014_bib60","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1093\/ndt\/gfq256","article-title":"Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus","volume":"25","author":"Catapano","year":"2010","journal-title":"Nephrol. Dial. Transpl."},{"key":"10.1016\/j.jaut.2016.06.014_bib61","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2215\/CJN.04030808","article-title":"Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome","volume":"4","author":"Melander","year":"2009","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.jaut.2016.06.014_bib62","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1093\/ndt\/gfp002","article-title":"Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study","volume":"24","author":"Boletis","year":"2009","journal-title":"Nephrol. Dial. Transpl."},{"key":"10.1016\/j.jaut.2016.06.014_bib63","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1136\/annrheumdis-2012-201442","article-title":"Rituximab versus oral cyclophosphamide for treatment of relapses of proliferative lupus nephritis: a clinical observational study","volume":"71","author":"Moroni","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2016.06.014_bib64","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1177\/0961203312446627","article-title":"Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study","volume":"21","author":"Fern\u00e1ndez-Nebro","year":"2012","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2016.06.014_bib65","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1136\/annrheumdis-2012-202844","article-title":"Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids","volume":"72","author":"Condon","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2016.06.014_bib66","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3109\/s10165-007-0565-z","article-title":"A\u00a0multicenter phase I\/II trial of rituximab for refractory systemic lupus erythematosus","volume":"17","author":"Tanaka","year":"2007","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.jaut.2016.06.014_bib67","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1136\/ard.2007.079095","article-title":"Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response","volume":"67","author":"J\u00f3nsd\u00f3ttir","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2016.06.014_bib68","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/0961203308094653","article-title":"Effects of rituximab on resistant SLE disease including lung involvement","volume":"18","author":"Reynolds","year":"2009","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2016.06.014_bib69","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/art.24341","article-title":"A\u00a0retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients","volume":"61","author":"Lu","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2016.06.014_bib70","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1002\/art.30466","article-title":"B\u00a0cell biomarkers of rituximab responses in systemic lupus erythematosus","volume":"63","author":"Vital","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2016.06.014_bib71","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1093\/rheumatology\/ker018","article-title":"The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation","volume":"50","author":"Turner-Stokes","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2016.06.014_bib72","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1177\/0961203309106174","article-title":"Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases","volume":"18","author":"Ramos-Casals","year":"2009","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2016.06.014_bib73","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1177\/0961203310395802","article-title":"Assessment of flares in lupus patients enrolled in a phase II\/III study of rituximab (EXPLORER)","volume":"20","author":"Merrill","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2016.06.014_bib74","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1093\/rheumatology\/ker526","article-title":"B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels","volume":"51","author":"Lazarus","year":"2012","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2016.06.014_bib75","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1172\/JCI38010","article-title":"The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus","volume":"119","author":"Cancro","year":"2009","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.jaut.2016.06.014_bib76","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/art.38074","article-title":"Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus","volume":"65","author":"Carter","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2016.06.014_bib77","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/ard.2007.079418","article-title":"B\u00a0cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response","volume":"67","author":"Cambridge","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2016.06.014_bib78","article-title":"Successful treatment of refractory lupus nephritis by the sequential use of rituximab and belimumab","author":"Simonetta","year":"2016","journal-title":"Jt. Bone Spine."},{"key":"10.1016\/j.jaut.2016.06.014_bib79","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1093\/rheumatology\/keu369","article-title":"YK. Belimumab after rituximab as maintenance therapy in lupus nephritis","volume":"53","author":"Kraaij","year":"2014","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2016.06.014_bib80","first-page":"449","article-title":"Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry","volume":"33","author":"Iaccarino","year":"2015","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jaut.2016.06.014_bib81","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1002\/art.27541","article-title":"Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry","volume":"62","author":"Terrier","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2016.06.014_bib82","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1177\/0961203313503912","article-title":"German Registry of Autoimmune Diseases (GRAID) Investigators. Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID)","volume":"22","author":"Witt","year":"2013","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2016.06.014_bib83","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.autrev.2011.10.009","article-title":"UK-BIOGEAS Registry. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts","volume":"11","author":"D\u00edaz-Lagares","year":"2012","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2016.06.014_bib84","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrrheum.2014.33","article-title":"The BAFF\/APRIL system in SLE pathogenesis","volume":"10","author":"Vincent","year":"2014","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.jaut.2016.06.014_bib85","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1002\/art.33458","article-title":"Dispensability of APRIL to the development of systemic lupus erythematosus in NZM 2328 mice","volume":"64","author":"Jacob","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2016.06.014_bib86","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s11926-012-0258-2","article-title":"The rationale for BAFF inhibition in systemic lupus erythematosus","volume":"14","author":"Davidson","year":"2012","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.jaut.2016.06.014_bib87","article-title":"Belimumab decreases flare frequency and hinders the expected damage progression in patients with active systemic lupus erythematosus: data from clinical practice setting","author":"Iaccarino","year":"2016","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2016.06.014_bib88","doi-asserted-by":"crossref","DOI":"10.1177\/0961203315625119","article-title":"Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care","author":"Bruce","year":"2016","journal-title":"Lupus."},{"key":"10.1016\/j.jaut.2016.06.014_bib89","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3899\/jrheum.121368","article-title":"LBSL02\/99 Study Group. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus","volume":"41","author":"Ginzler","year":"2014","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.jaut.2016.06.014_bib90","doi-asserted-by":"crossref","DOI":"10.1002\/art.39682","article-title":"Cumulative corticosteroids over 52 weeks in patients with systemic lupus erythematosus: pooled analyses from the phase III belimumab trials","author":"van Vollenhoven","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2016.06.014_bib91","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1136\/annrheumdis-2011-200937","article-title":"Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response","volume":"71","author":"van Vollenhoven","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2016.06.014_bib92","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/annrheumdis-2015-208312","article-title":"Targeting BAFF\/BLyS in lupus: is the glass half-full or half-empty?","volume":"75","author":"Houssiau","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2016.06.014_bib93","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1177\/0961203315608254","article-title":"Association of BAFF, APRIL serum levels, BAFF-R, TACI and BCMA expression on peripheral B-cell subsets with clinical manifestations in systemic lupus erythematosus","volume":"25","author":"Salazar-Camarena","year":"2016","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2016.06.014_bib94","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/art.38950","article-title":"BAFF regulates follicular helper T cells and affects their accumulation and interferon production in autoimmunity","volume":"67","author":"Coquery","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2016.06.014_bib95","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/art.38951","article-title":"Editorial: the BAFFling immunology of systemic lupus erythematosus: beyond B cells","volume":"67","author":"Stohl","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2016.06.014_bib96","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/art.10856","article-title":"BG9588 Lupus Nephritis Trial Group. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis","volume":"48","author":"Boumpas","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2016.06.014_bib97","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.1002\/art.34624","article-title":"Abatacept for lupus nephritis. Alternative definitions of complete response support conflicting conclusions","volume":"64","author":"Wosfy","year":"2012","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2016.06.014_bib98","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1053\/j.ajkd.2013.11.023","article-title":"Lupus nephritis: the evolving role of novel therapeutics","volume":"63","author":"Rovin","year":"2014","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.jaut.2016.06.014_bib99","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s40265-015-0394-x","article-title":"Targeting interferons in systemic lupus erythematosus: current and future prospects","volume":"75","author":"Mathian","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.jaut.2016.06.014_bib100","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1136\/annrheumdis-2012-203041","article-title":"TLR9 independent interferon \u03b1 production by neutrophils on NETosis in response to circulating chromatin, a key lupus autoantigen","volume":"73","author":"Lindau","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2016.06.014_bib101","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1136\/ard.2004.033753","article-title":"Type I interferon correlates with serological and clinical manifestations of SLE","volume":"64","author":"Dall\u2019Era","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2016.06.014_bib102","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/art.23186","article-title":"Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: role of interleukin-18","volume":"58","author":"Tucci","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2016.06.014_bib103","unstructured":"C. Morehouse, L. Chang, L. Wang, P. Brohawan, S. Uead, G. Illei, et\u00a0al. Target modulation of a type I interferon gene signature with sifalimumab or anifrolumab in SLE patients in two open labels phase II Japanese trials. Abstract no. 719 presented at the ACR\/ARHP annual meeting, Boston, MA, November 15-19, 2014."},{"key":"10.1016\/j.jaut.2016.06.014_bib104","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/art.37785","article-title":"Down-regulation of interferon signature in SLE patients by active immunization with interferon alpha kinoid","volume":"64","author":"Lauwerys","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2016.06.014_bib105","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1177\/096120339600500603","article-title":"Serum and urinary interleukin-6 in systemic lupus erythematosus","volume":"5","author":"Peterson","year":"1996","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2016.06.014_bib106","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/art.1780340305","article-title":"In\u00a0vitro regulation of B cell differentiation by interleukin-6 and soluble CD23 in systemic lupus erythematosus B cell subpopulations and antigen-induced normal B cells","volume":"34","author":"Klashman","year":"1991","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2016.06.014_bib107","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1365-2567.2006.02433.x","article-title":"Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus","volume":"119","author":"Liang","year":"2006","journal-title":"Immunology"},{"key":"10.1016\/j.jaut.2016.06.014_bib108","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1681\/ASN.V4158","article-title":"Interleukin-6 receptor blockage ameliorates murine lupus nephritis","volume":"4","author":"Kiberd","year":"1993","journal-title":"J.\u00a0Am. Soc. Nephrol."},{"key":"10.1016\/j.jaut.2016.06.014_bib109","doi-asserted-by":"crossref","DOI":"10.1002\/art.39722","article-title":"A\u00a0multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of treatment with sirukumab (CNTO 136) in patients with active lupus nephritis","author":"Rovin","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2016.06.014_bib110","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.27221","article-title":"Tocilizumab in systemic lupus erythematosus","volume":"62","author":"Illei","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2016.06.014_bib111","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1002\/art.37940","article-title":"Comparison of alternative primary outcome measures for use in lupus nephritis clinical trials","volume":"65","author":"Wosfy","year":"2013","journal-title":"Arthritis Rheum."},{"issue":"Suppl.\u00a03","key":"10.1016\/j.jaut.2016.06.014_bib112","article-title":"Disease activity assessment in SLE: do we have the right instruments?","volume":"66","author":"Petri","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2016.06.014_bib113","article-title":"Comparison and evaluation of lupus nephritis response criteria in lupus activity indices and clinical trials","volume":"28","author":"Corapi","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2016.06.014_bib114","first-page":"671","article-title":"A\u00a0comparison of rheumatoid arthritis and systemic lupus erythematosus trial design: a commentary on ways to improve the number of positive trials in SLE","volume":"33","author":"Miles","year":"2015","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jaut.2016.06.014_bib115","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/nrrheum.2009.79","article-title":"Systemic lupus erythematosus clinical trials-an interim analysis","volume":"5","author":"Dall\u2019Era","year":"2009","journal-title":"Nat. Rev. Rheumatol."}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841116300920?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841116300920?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:18:10Z","timestamp":1760257090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841116300920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":115,"alternative-id":["S0896841116300920"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2016.06.014","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Success and failure of biological treatment in systemic lupus erythematosus: A critical analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2016.06.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}